Colorectal cancer study to be discontinued
NuCana has revealed that the NuTide:323 colorectal cancer study is being discontinued following a pre-planned initial analysis and recommendation from the NuTide:323 Study Steering Committee. The Steering Committee believed that the combination of NUC-3373 with leucovorin, irinotecan and bevacizumab (NUFIRI+bev) was unlikely to achieve the study’s… Read More